ArticleResearch square2026
A Framework for Locally Imputing and Predicting Biomarker Trajectories Under Irregular Monitoring: Application to Chronic Myeloid Leukemia.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Irregular monitoring and missing data limit the utility of longitudinal biomarkers in real-world practice. We developed a generalizable framework that combines interval-aligned preprocessing, localized multiple imputation, and machine-learning forecasting to generate complete trajectories and predict future biomarker values under routine clinical conditions. Using BCR::ABL1 monitoring in chronic myeloid leukemia as a case study, we aligned measurements to 90-day intervals, applied a windowed, uncertainty-propagating imputation strategy, and trained recurrent neural network (RNN) and XGBoost models to forecast values three and six months ahead. Full Information models achieved RMSEs of 1.22-1.24 for 3-month predictions-well below the biomarker's observed variability-and maintained accuracy even when the most recent visit was intentionally omitted, simulating extended follow-up. This framework preserves local temporal structure, supports individualized monitoring decisions, and is directly adaptable to other continuous biomarkers measured under irregular real-world schedules.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.